Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 52:1749-1757, doi:10.1016/j.jacc.2008.08.036
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarafidis, P. A.
Right arrow Articles by Bakris, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarafidis, P. A.
Right arrow Articles by Bakris, G. L.
Related Collections
Right arrowRelated Article

STATE-OF-THE-ART PAPER

Resistant Hypertension

An Overview of Evaluation and Treatment

Pantelis A. Sarafidis, MD, PhD* and George L. Bakris, MD, FAHA, FASN{dagger},*

* Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
{dagger} Hypertensive Diseases Unit, Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois

Manuscript received June 20, 2008; revised manuscript received August 18, 2008, accepted August 26, 2008.

* Reprint requests and correspondence: Dr. George L. Bakris, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, Illinois 60637 (Email: gbakris{at}gmail.com).

Resistant hypertension is defined as failure to achieve goal blood pressure (BP) when a patient adheres to the maximum tolerated doses of 3 antihypertensive drugs including a diuretic. Although the exact prevalence of resistant hypertension is currently unknown, indirect evidence from population studies and clinical trials suggests that it is a relatively common clinical problem. The prevalence of resistant hypertension is projected to increase, owing to the aging population and increasing trends in obesity, sleep apnea, and chronic kidney disease. Management of resistant hypertension must begin with a careful evaluation of the patient to confirm the diagnosis and exclude factors associated with "pseudo-resistance," such as improper BP measurement technique, the white-coat effect, and poor patient adherence to life-style and/or antihypertensive medications. Education and reinforcement of life-style issues that affect BP, such as sodium restriction, reduction of alcohol intake, and weight loss if obese, are critical in treating resistant hypertension. Exclusion of preparations that contribute to true BP treatment resistance, such as nonsteroidal anti-inflammatory agents, cold preparations, and certain herbs, is also important. Lastly, BP control can only be achieved if an antihypertensive treatment regimen is used that focuses on the genesis of the hypertension. An example is volume overload, a common but unappreciated cause of treatment resistance. Use of the appropriate dose and type of diuretic provides a solution to overcome treatment resistance in this instance.

Key Words: resistant hypertension • management • evaluation • treatment

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  ARB = angiotensin-receptor blocker
  BP = blood pressure
  CCB = calcium-channel blocker
  eGFR = estimated glomerular filtration rate
  ERA = endothelin-receptor antagonist
  NSAID = nonsteroidal anti-inflammatory drug
  RAS = renin-angiotensin system


Related Article

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A36. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Rossi, A. Nuzzo, D. Iaccarino, A. Lattanzi, G. Origliani, D. E. Monopoli, and M. G. Modena
Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2011; 12(4): 446 - 455.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. D. Bisognano, G. Bakris, M. K. Nadim, L. Sanchez, A. A. Kroon, J. Schafer, P. W. de Leeuw, and D. A. Sica
Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension: Results From the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial
J. Am. Coll. Cardiol., August 9, 2011; 58(7): 765 - 773.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
Symplicity HTN-1 Investigators
Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months
Hypertension, May 1, 2011; 57(5): 911 - 917.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Volpe and G. Tocci
Rethinking targets of blood pressure and guidelines for hypertension clinical management
Nephrol. Dial. Transplant., November 1, 2010; 25(11): 3465 - 3471.
[Full Text] [PDF]


Home page
HypertensionHome page
G. L. Bakris, L. H. Lindholm, H. R. Black, H. Krum, S. Linas, J. V. Linseman, S. Arterburn, P. Sager, and M. Weber
Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
Hypertension, November 1, 2010; 56(5): 824 - 830.
[Abstract] [Full Text] [PDF]


Home page
cfpHome page
On behalf of the Canadian Hypertension Education P
2010 Canadian Hypertension Education Program recommendations: An annual update
Can Fam Physician, July 1, 2010; 56(7): 649 - 653.
[Full Text] [PDF]


Home page
J Am Osteopath AssocHome page
K. J. Tobin
Stable Angina Pectoris: What Does the Current Clinical Evidence Tell Us?
J Am Osteopath Assoc, July 1, 2010; 110(7): 364 - 370.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
G. Mancia, G. Parati, and A. Zanchetti
Electrical Carotid Baroreceptor Stimulation in Resistant Hypertension
Hypertension, March 1, 2010; 55(3): 607 - 609.
[Full Text] [PDF]


Home page
CirculationHome page
B. A. Maron and J. A. Leopold
Aldosterone Receptor Antagonists: Effective but Often Forgotten
Circulation, February 23, 2010; 121(7): 934 - 939.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. Ritz and A. Tomaschitz
Aldosterone, a vasculotoxic agent--novel functions for an old hormone
Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2302 - 2305.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. Kapoor and J. R. Kapoor
Blood Pressure Reduction With Potassium Supplementation
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1164 - 1164.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. A. Sarafidis and G. L. Bakris
Reply
J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1164 - 1165.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement